SLRX: מכפיל P/S Salarius

The absence of commercial products leaves Salarius Pharmaceuticals (SLRX) dependent on venture capital investments. The current P/S valuation on the GURU.Markets terminal illustrates a chart of the metric, where the value 20.40 represents the most recent figure. Business stability is supported by the non-cyclical nature of oncology, while trial safety is guaranteed by strict adherence to the cold chain during component transportation.

The P/S ratio correlates the market capitalization of Salarius Pharmaceuticals (SLRX) with its revenue, revealing valuation premiums relative to operational efficiency. Analyzing the company's historical P/S value helps identify capital correction risks in the absence of sales growth, which is critical for assessing the expansion potential of Ewing sarcoma drugs and solid tumor therapies within oncology centers.